Cargando…
Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8(+)β7 integrin(+) T cells and anti-SARS-CoV-2 IgA response
Several millions of individuals are estimated to develop post-acute sequelae SARS-CoV-2 condition (PASC) that persists for months after infection. Here we evaluate the immune response in convalescent individuals with PASC compared to convalescent asymptomatic and uninfected participants, six months...
Autores principales: | Santa Cruz, André, Mendes-Frias, Ana, Azarias-da-Silva, Marne, André, Sónia, Oliveira, Ana Isabel, Pires, Olga, Mendes, Marta, Oliveira, Bárbara, Braga, Marta, Lopes, Joana Rita, Domingues, Rui, Costa, Ricardo, Silva, Luís Neves, Matos, Ana Rita, Ângela, Cristina, Costa, Patrício, Carvalho, Alexandre, Capela, Carlos, Pedrosa, Jorge, Castro, António Gil, Estaquier, Jérôme, Silvestre, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061413/ https://www.ncbi.nlm.nih.gov/pubmed/36997530 http://dx.doi.org/10.1038/s41467-023-37368-1 |
Ejemplares similares
-
Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia
por: Santa Cruz, André, et al.
Publicado: (2021) -
Prediction of Noninvasive Ventilation Failure in COVID-19 Patients: When Shall We Stop?
por: Neves da Silva, Luís, et al.
Publicado: (2022) -
Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients
por: André, Sonia, et al.
Publicado: (2022) -
Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
por: Azarias Da Silva, Marne, et al.
Publicado: (2023) -
Analysis of Salivary Levels of IL-1β, IL17A, OPG and RANK-L in Periodontitis Using the 2017 Classification of Periodontal Diseases—An Exploratory Observational Study
por: Relvas, Marta, et al.
Publicado: (2023)